Connection
Larry Moreland to Cost-Benefit Analysis
This is a "connection" page, showing publications Larry Moreland has written about Cost-Benefit Analysis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.145 |
|
|
|
-
Jalal H, O'Dell JR, Bridges SL, Cofield S, Curtis JR, Mikuls TR, Moreland LW, Michaud K. Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016 12; 68(12):1751-1757.
Score: 0.101
-
Gabriel SE, Coyle D, Moreland LW. A clinical and economic review of disease-modifying antirheumatic drugs. Pharmacoeconomics. 2001; 19(7):715-28.
Score: 0.034
-
Alarcón GS, Moreland LW, Sillers MJ, Morgan E, Carroll WR. A 2-phase screening process for patients with Wegener's granulomatosis: a pilot study. J Rheumatol. 2003 Nov; 30(11):2420-1.
Score: 0.010